(50 days)
No
The document describes image viewing, manipulation, visualization, and comparison tools with some automated features like reorientation and calculation of Lung CAD results, but it does not explicitly mention or describe the use of AI or ML algorithms for these functions. The focus is on workflow enhancement and visualization, not on learning or adaptive capabilities.
No.
The device is described as a "medical diagnostic application" for viewing, manipulating, and comparing medical images, and for providing analytical tools to help assess and document changes in morphological or functional activity. Its intended use is for interpretation, evaluation, and follow-up documentation of findings. It does not actively treat or directly affect the patient's body to cure or alleviate a disease, injury, or condition.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states that "syngo.via MI Workflows are medical diagnostic applications" and provide "analytical tools to help the user assess, and document changes in morphological or functional activity at diagnostic and therapy follow-up examinations." The "Device Description" also reiterates that it is a "medical diagnostic application."
Yes
The device description explicitly states "The syngo.via MI Workflows are software only medical devices".
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to perform tests on samples taken from the human body (like blood, urine, tissue) to provide information about a person's health.
- Device Function: The syngo.via MI Workflows are described as software for viewing, manipulating, and analyzing medical images from various imaging modalities (PET, SPECT, CT, MR). It helps in the interpretation and evaluation of these images for diagnostic and follow-up purposes.
- Lack of Sample Analysis: The device does not perform any analysis on biological samples. Its input is medical imaging data.
Therefore, while it is a medical diagnostic device, it falls under the category of medical image processing and analysis software, not In Vitro Diagnostics.
N/A
Intended Use / Indications for Use
syngo.via MI Workflows are medical diagnostic applications for viewing, manipulation, 3D- visualization and comparison of medical images from multiple imaging modalities and/or multiple time-points. The application supports functional data, such as PET or SPECT as well as anatomical datasets, such as CT or MR.
syngo.via MI Workflows enable visualization of information that would otherwise have to be visually compared disjointedly. syngo.via MI Workflows provide analytical tools to help the user assess, and document changes in morphological or functional activity at diagnostic and therapy follow-up examinations. syngo.via MI Workflows can perform harmonization of SUV (PET) across different PET systems or different reconstruction methods.
syngo via MI workflows support the interpretation and evaluation and follow up documentation of findings within healthcare institutions, for example, in Radiology, Nuclear Medicine and Cardiology environments.
Note: The clinician retains the ultimate responsibility for making the pertinent diagnosis based on their standard practices and visual comparison of the separate unregistered images. syngo.via MI Workflows are a complement to these standard procedures.
Product codes
LLZ
Device Description
The syngo.via MI Workflows are software only medical devices which will be delivered on CD-ROM / DVD to be installed onto the commercially available Siemens syngo.via software platform by trained service personnel.
syngo.via MI Workflows is a medical diagnostic application for viewing, manipulation, 3Dvisualization and comparison of medical images from multiple imaqinq modalities and/or multiple time-points. The application supports functional data, such as PET or SPECT as well as anatomical datasets, such as CT or MR. The images can be viewed in a number of output formats including MIP and volume rendering.
syngo.via MI Workflows enable visualization of information that would otherwise have to be visually compared disiointedly. syngo.via MI Workflows provide analytical tools to help the user assess, and document changes in morphological or functional activity at diagnostic and therapy follow-up examinations. They additionally support the interpretation and evaluation of examinations and follow up documentation of findings within healthcare institutions, for example, in Radiology (Oncology), Nuclear Medicine and Cardiology environments.
The modifications to the syngo.via MI Workflows (K133644) include the following new features:
syngo.MM Oncology
- Color-coded seqmentations on VRTs indicating the rate of growth or shrinkage
- . Support for additional annotation information that allows the user to adhere to the QIBA protocol for lung nodule assessment
- Acquisition Bundles for consistent and intuitive management of data sets
- Addition of RT Nudge Tool for GTV editing o
- OncoBoard for reviewing studies in multi-disciplinary teams
- Rapid Result Technology automatically calculates and sends Lung CAD results as a o DICOM series within the workflow
syngo.MI Reading
- Further integration of MI Reading with the Cardiology and Neurology ● functionality including volume stripe view and neuro & cardio orientation display
- Snap-back functionality to help re-orientate volumes
syngo.MI Cardiology
- Implementation of display and manipulation of cardiac data in standard cardiac . views instead of using third party applications to do this
- Automatic cardiac reorientation
- o Support for the updated Corridor 4DM 2015, Cedars 2015, and CFR VB14 versions
syngo.MI Neurology
- Implementation of display and manipulation of brain data in standard brain views ●
- Automatic brain reorientation .
- Support for the latest version of Scenium VD20 .
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
multiple imaging modalities, PET, SPECT, CT, MR
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
healthcare institutions, for example, in Radiology, Nuclear Medicine and Cardiology environments.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The device labeling contains instructions for use and any necessary cautions and warnings to provide for safe and effective use of the device.
Risk Management has been ensured via risk analyses in compliance with ISO 14971:2012 to identify and provide mitigation to potential hazards beginning early in the design cycle and continuing throughout the development of the product. Siemens Medical Solutions, USA Inc. adheres to recognized and established industry standards for development including ISO 13485 and IEC 62304.
Verification and Validation activities have been successfully performed on the software packaqe, including assurance that functions work as designed, performance requirements and specifications have been met, and that all hazard mitigations have been fully implemented. All testing has met the predetermined acceptance values. Traceability of the requirements specified in the requirement specifications and functional specifications is ensured during component integration, software validation and system testing.
The device is designed and manufactured in accordance with Quality System Requlations as outlined in 21 CFR 820.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized graphic of three human profiles facing to the right, stacked on top of each other, with flowing lines extending from the bottom profile.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
June 23, 2015
Siemens Medical Solutions USA, Inc. % Ms. Veronica Padharia Regulatory Affairs Specialist 2501 N. Barrington Road HOFFMAN ESTATES IL 60192
Re: K151192
Trade/Device Name: syngo.via MI Workflows VB10A Software Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: May 1, 2015 Received: May 11, 2015
Dear Ms. Veronica:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Michael O'Hara
For
Robert Ochs, Ph.D. Acting Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name
syngo.via MI Workflows VB10A Software
Indications for Use (Describe)
syngo.via MI Workflows are medical diagnostic applications for viewing, manipulation, 3D- visualization and comparison of medical images from multiple imaging modalities and/or multiple time-points. The application supports functional data, such as PET or SPECT as well as anatomical datasets, such as CT or MR.
syngo.via MI Workflows enable visualization of information that would otherwise have to be visually compared disjointedly. syngo.via MI Workflows provide analytical tools to help the user assess, and document changes in morphological or functional activity at diagnostic and therapy follow-up examinations. syngo.via MI Workflows can perform harmonization of SUV (PET) across different PET systems or different reconstruction methods.
syngo via MI workflows support the interpretation and evaluation and follow up documentation of findings within healthcare institutions, for example, in Radiology, Nuclear Medicine and Cardiology environments.
Note: The clinician retains the ultimate responsibility for making the pertinent diagnosis based on their standard practices and visual comparison of the separate unregistered images. syngo.via MI Workflows are a complement to these standard procedures.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| X Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
as required by 21 CFR Part 807.87(h)
Identification of the Submitter
| Primary Contact: | Alternate Contact: | |
|---|---|---|
| Submitter: | Veronica Padharia | |
| Regulatory Affairs Specialist | ||
| Siemens Medical Solutions | ||
| USA, Inc. | ||
| Molecular Imaging | ||
| 2501 Barrington Road | ||
| Hoffman Estates, IL 60192 | M. Alaine Medio, RAC | |
| PET and PCS Regulatory | ||
| Projects Manager | ||
| Siemens Medical Solutions | ||
| USA, Inc. | ||
| Molecular Imaging | ||
| 810 Innovation Drive | ||
| Knoxville, TN 37932 | ||
| Telephone Number: | (630) 877 – 5761 | (865)218 - 2703 |
| Fax Number: | (847) 304 - 6023 | (865)218 - 3019 |
| Name / Address of | ||
| Manufacturer | Siemens Medical Solutions USA, Inc | |
| Molecular Imaging | ||
| 2501 N. Barrington Road | ||
| Hoffman Estates, IL 60192 | ||
| USA | ||
| Date of Submission: | May 1, 2015 | |
| Device Proprietary Name: | syngo.via MI Workflows VB10A | |
| Common Name: | Image Processing Software | |
| Classification Name: | Picture Archiving and Communication System per 21 CFR | |
| 892.2050 | ||
| Product Code: | LLZ | |
| Classification Panel: | Radiology | |
| Device Class: | Class II |
4
Marketed Devices to which Equivalence is claimed
| Device | Manufacturer | 510(k) Number |
|---|---|---|
| syngo.via MI | ||
| Workflows VA30A | Siemens Medical Solutions USA, Inc | K133644 (February 25, 2014) |
Device Description
The syngo.via MI Workflows are software only medical devices which will be delivered on CD-ROM / DVD to be installed onto the commercially available Siemens syngo.via software platform by trained service personnel.
syngo.via MI Workflows is a medical diagnostic application for viewing, manipulation, 3Dvisualization and comparison of medical images from multiple imaqinq modalities and/or multiple time-points. The application supports functional data, such as PET or SPECT as well as anatomical datasets, such as CT or MR. The images can be viewed in a number of output formats including MIP and volume rendering.
syngo.via MI Workflows enable visualization of information that would otherwise have to be visually compared disiointedly. syngo.via MI Workflows provide analytical tools to help the user assess, and document changes in morphological or functional activity at diagnostic and therapy follow-up examinations. They additionally support the interpretation and evaluation of examinations and follow up documentation of findings within healthcare institutions, for example, in Radiology (Oncology), Nuclear Medicine and Cardiology environments.
The modifications to the syngo.via MI Workflows (K133644) include the following new features:
syngo.MM Oncology
- Color-coded seqmentations on VRTs indicating the rate of growth or shrinkage
- . Support for additional annotation information that allows the user to adhere to the QIBA protocol for lung nodule assessment
- Acquisition Bundles for consistent and intuitive management of data sets
- Addition of RT Nudge Tool for GTV editing o
- OncoBoard for reviewing studies in multi-disciplinary teams
- Rapid Result Technology automatically calculates and sends Lung CAD results as a o DICOM series within the workflow
syngo.MI Reading
- Further integration of MI Reading with the Cardiology and Neurology ● functionality including volume stripe view and neuro & cardio orientation display
- Snap-back functionality to help re-orientate volumes
syngo.MI Cardiology
- Implementation of display and manipulation of cardiac data in standard cardiac . views instead of using third party applications to do this
5
- Automatic cardiac reorientation
- o Support for the updated Corridor 4DM 2015, Cedars 2015, and CFR VB14 versions
syngo.MI Neurology
- Implementation of display and manipulation of brain data in standard brain views ●
- Automatic brain reorientation .
- Support for the latest version of Scenium VD20 .
Technological Characteristics
The syngo.via MI Workflows VB10A software modifications are based on the commercially available syngo.via VA30A software (K133644). The features introduced into syngo.via VB10A had no impact on the technological characteristics already present in the commercially available predicate system.
syngo.via MI Workflows is intended to be run on the Siemens syngo.via software platform (K150843) either alone or with other advanced commercially cleared applications.
Performance Testing / Safety and Effectiveness
The device labeling contains instructions for use and any necessary cautions and warnings to provide for safe and effective use of the device.
Risk Management has been ensured via risk analyses in compliance with ISO 14971:2012 to identify and provide mitigation to potential hazards beginning early in the design cycle and continuing throughout the development of the product. Siemens Medical Solutions, USA Inc. adheres to recognized and established industry standards for development including ISO 13485 and IEC 62304.
Verification and Validation activities have been successfully performed on the software packaqe, including assurance that functions work as designed, performance requirements and specifications have been met, and that all hazard mitigations have been fully implemented. All testing has met the predetermined acceptance values. Traceability of the requirements specified in the requirement specifications and functional specifications is ensured during component integration, software validation and system testing.
The device is designed and manufactured in accordance with Quality System Requlations as outlined in 21 CFR 820.
Indications for Use
syngo.via MI Workflows are medical diagnostic applications for viewing, manipulation, 3Dvisualization and comparison of medical images from multiple imaqinq modalities and/or multiple time-points. The application supports functional data, such as PET or SPECT as well as anatomical datasets, such as CT or MR.
syngo.via MI Workflows enable visualization of information that would otherwise have to be visually compared disjointedly. synqo.via MI Workflows provide analytical tools to help the user assess, and document changes in morphological or functional activity at diagnostic and therapy follow-up examinations. syngo.via MI Workflows can perform harmonization of SUV (PET) across different PET systems or different reconstruction methods.
6
syngo.via MI Workflows support the interpretation and evaluation of examinations and follow up documentation of findings within healthcare institutions, for example, in Radiology, Nuclear Medicine and Cardiology environments.
Note: The clinician retains the ultimate responsibility for making the pertinent diagnosis based on their standard practices and visual comparison of the separate unreqistered images. syngo.via MI Workflows are a complement to these standard procedures.
Statement Regarding Substantial Equivalence:
There are no differences in the Indications for Use or Fundamental Technological Characteristics of the syngo.via MI Workflows as compared to the currently commercially available software (K133644). Both devices are used for viewing, manipulation, 3Dvisualization and comparison of medical images from multiple imaging modalities and/or multiple time-points
Additionally, there have been no changes that raise any new issues of safety and effectiveness as compared to the predicate device. Based on this information, as well as the documentation in support of the modifications, it is Siemens opinion that the syngo.via MI Workflows software with the modifications outlined in this application is substantially equivalent to the predicate device.